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Abstract
Background: An altered expression of the activated leukocyte cell adhesion molecule (ALCAM) is associated with
cancer progression in various cancer types. In some cancers ALCAM has a prognostic value or is predictive for the
benefit of therapeutic interventions. To date there are no data on the role of ALCAM in cervical cancer available.
Methods: In this study, ALCAM expression was analysed by immunohistochemistry (IHC) in tissue samples of 233
patients with cervical cancer, among them 178 with complete follow-up information. In addition, soluble (s-)
ALCAM was measured in sera of a subset of the included patients (n = 55) by enzyme-linked immunosorbent
assay (ELISA).
Results: ALCAM overexpression was detected (immunoreactive score (IRS) 2-12) in 58.4% of the cervical cancer
samples. The normal ectocervical or endocervical epithelium showed no ALCAM reactivity. In untreated patients,
ALCAM overexpression in tumor tissue tended to be associated with shorter cancer-specific survival (CSS) and
disease-free survival (DFS). Patients, whose tumor samples showed ALCAM overexpression receiving a cytotoxic
therapy like radiotherapy or chemoradiation, however, had a favourable prognosis compared to those patients,
whose cancers showed no or minimal ALCAM staining. This effect was particularly apparent in patients receiving
chemoradiation where the CSS was significantly longer in patients with ALCAM-positive tumors (p = 0.038;
cumulative incidence rates at 96 months 8%, 95% CI 0%-23%, and 26%, CI 3%-43% in ALCAM-positive and ALCAM-
negative cases, respectively).
Median preoperative s-ALCAM concentration in sera from tumor patients was 27.6 ng/ml (range 17.5-55.1 ng/ml,
mean 28.9 ng/ml), serum levels did not correlate with intratumoral ALCAM expression.
Conclusions: The data of our retrospective study suggest that the prognostic value of ALCAM expression in
cervical carcinoma might be therapy-dependent, and that ALCAM might function as a predictive marker for the
response to chemoradiation. This should be confirmed in further, prospective studies.
Background
Cervical cancer is the third most common malignancy
in women, accounting for 8.8% of all cancers. World-
wide there were estimated 529,000 new cases in 2008
and 274,000 deaths due to cervical cancer [1]. Locally
advanced cervical cancers (stage IB2-IVA) are generally
treated by primary chemoradiotherapy http://www.nccn.
org, http://www.ago-online.org. In early stage disease
(FIGO 0 to IB1) and also in stage IIA cancers, treatment
guidelines give several treatment choices to the oncolo-
gists and therapeutic decisions are often subject to dis-
cussion. Therapeutic options include surgery with or
without radiotherapy or concomitant chemoradiother-
apy. The applied regimens have various side effects,
especially when treatment modalities (surgery and che-
moradiotherapy) are combined. However, predictive fac-
tors for the benefit of chemo- and or radiotherapy in
the treatment of this disease remain scarse [2].
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superfamily of adhesion molecules (IgCAMs). IgCAMs
are mostly transmembrane proteins, functioning not
only as cell adhesion receptors, but also transducing sig-
nals to intracellular signalling pathways [3]. ALCAM
expression has been described in subsets of cells being
involved in dynamic growth and migration but it has
also been detected in cancer stem cells [4]. In various
neoplasms like malignant melanoma [5], prostate cancer
[6], colorectal carcinoma [7], bladder cancer [8] and
breast cancer [9] as well as in oral [10] and esophageal
squamous cell cancer [11] a pathologically altered
ALCAM expression has been observed and was asso-
ciated with cancer progression. On the other hand,
ALCAM expression in tumor tissue has been reported
to be a potential marker for the benefit of therapeutical
interventions: Previous studies of our group and others
could show that ALCAM expression predicted che-
motherapy response in early breast cancer [12] and pan-
creatic cancer cells [13]. The extracellular domain of
ALCAM can be shedded by proteases [14]. Recent stu-
dies measured soluble ALCAM levels (s-ALCAM) in
blood serum of tumor patients, e.g. breast cancer, sug-
gesting a potential value of s-ALCAM as a biomarker
for cancer detection [15]. No data is available for the
role of ALCAM or s-ALCAM in cervical cancer so far.
In this hypothesis generating study we analysed
ALCAM expression in cervical cancer tissue and its cor-
relation with clinico-pathological tumor characteristics.
In addition, we examined the prognostic and predictive
impact of ALCAM expression in cervical cancer and s-
ALCAM expression in sera of a subset of patients. We
could demonstrate that ALCAM expression in cervical
cancer could function as a marker for improved out-
come in patients treated with radiotherapy or
chemoradiotherapy.
Methods
Patients
Tumor tissue of 233 patients undergoing surgery for
primary cervical cancer in 4 different hospitals between
1993 and 2008 was analyzed. For 178 patients detailed
follow-up data from the date of primary surgery to the
date of death or last contact (July 2009) were available.
Patient characteristics are listed in Tables 1 and 2. In
addition, 55 preoperative serum samples from a subset
of the included patients treated in one participating cen-
ter were analysed to detect s-ALCAM levels. To assure
the analysis of a representative cohort, FIGO stages in
this subcohort were compared to those of the whole
cohort showing a similar stage distribution (FIGO stage
I, 67%; stage II, 24%; stage III/IV, 9%; compare Table 1).
Clinicopathologic factors were evaluated by reviewing
medical charts and pathologic reports of the department
of gynecological pathology at University Medical Center
Hamburg-Eppendorf which acted as reference pathology.
Informed consent for the scientific use of patient data,
tumor tissue and serum had been obtained from all
patients in coordination with the local ethics committee
(Ethics committee of the Medical Board Hamburg, refer-
ence number #190504). All data were analyzed anon-
ymously. The study was performed in accordance to the
principles of the declaration of Helsinki and REMARK
criteria [16].
The treatment of cervical cancer patients during the
investigational period consisted of radical hysterectomy
and resection of the pelvic and paraaortic lymph nodes
using laparotomy for FIGO stages I and II. Only in
stage Ia and Ib disease with fertility preserving objective
radical hysterectomy was omitted. In cases of advanced
disease radio- and/or chemotherapy of the pelvis and
the paraaortic region was performed in accordance to
German Cancer Guidelines or in clinical trials. Depend-
ing on tumor size and nodal involvement mean radia-
tion dose was 50.4 Gy (range 45-55.8 Gy) due to the
dose prescription habits of the individual hospital and
dose volume histograms.
In our study, 25 patients were included who received
primary surgery, even though they had been diagnosed
Table 1 Cohort characteristics
n%
Total cohort (n = 233)
Age
Mean/median age 23-85 y
Range 49/47 y
Tumor stage (FIGO
Ia 4 (1.7)
Ib 139 (59.7)
IIa 17 (7.3)
IIb 48 (20.6)
IIIb 1 (0.4)
IVa 7 (3.0)
IVb 17 (7.4)
Postoperative residual tumor
R0 212 (91.0)
R1 21 (9.0)
Subcohort with follow-up informations (n = 178)
Applied therapy regimen
Observation 86 (48.3)
Adjuvant radiotherapy alone 42 (23.6)
Adjuvant chemoradiotherapy 50 (28.0)
Clinical follow-up
Median follow-up time: 49 months
Recurrence 47 (25.4)
Dead of disease (DOD) 41 (22.2)
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Page 2 of 10with FIGO stage III/IV disease. Although primary che-
moradiation is generally recommended in these cases,
surgery had been performed either to prevent further
tumor invasion into the bladder and/or rectum or
because there were no signs of distant disease apparent
before surgery.
In order to analyse the predictive value of ALCAM
expression, patients with complete follow-up data (n =
178) were stratified into untreated patients (n = 86),
patients who received adjuvant radiotherapy only (n =
42) and patients, who were treated by using a combina-
tion of chemotherapy and radiotherapy (chemoradiation;
n = 50). Applied chemotherapy in the subgroup with
follow-up information included cisplatin as single agent
or in combination with (n = 47), carboplatin/ifosfamide
(n = 2) or other regimens (n = 1).
Immunohistochemistry
Tissue processing was identical for all participating
laboratories. Fixation was performed by using 4% buf-
fered formalin. For evaluation all samples were sent as
paraffin-embedded tissue blocks to the department of
gynecological pathology, University Medical Center
Hamburg-Eppendorf.
Tissue sections were cut at 5 μm, mounted on slides,
dewaxed with xylene and gradually hydrated. Subse-
quently, the slides were placed in boiling 10 mM
citrate buffer for 30 min, washed in Aqua dest.,
immersed in 0,5% H2O2-methanol for 30 min and
washed again in TRIS buffered saline (TBS). For
immunohistochemistry, the Vectastain Elite ABC Kit -
Peroxidase (Mouse IgG; Vector Laboratories, Inc., Bur-
lingham, CA, U.S.A.) and the DAB Peroxidase Sub-
strate Kit (Vector Lab.) were applied. Incubation with
the primary ALCAM antibody (1:400; Vector Lab.) was
performed at 4°C overnight. The slides were briefly
counterstained with haematoxylin and dehydrated
before mounting. As positive control, an ALCAM-posi-
tive mammary tumor according to our own prior IHC
and Western blot results was included in each experi-
ment. For negative controls, the primary antibody was
omitted (not shown). The staining results were evalu-
ated independently by a gynaecologist and a gynaecolo-
gical pathologist using the immunoreactive score (IRS)
Table 2 Correlations between ALCAM expression and clinicopathological factors
ALCAM expression
All patients negative (IRS 0-1) positive (IRS 2-12) p-value
All samples 233 97 136
Histological subtype (n = 233) squamous 171 70 101
adenomatous 35 18 17
adenosquamous 27 9 18 0.338
FIGO stage (n = 233) I 143 60 83
II 65 25 40
III/IV 25 12 13 0.971
Nodal
involvement (n = 233)
pN0 175 75 100
pN1 58 22 36 0.542
Number of Positive lymph nodes (n = 233) 0 175 75 100
1-3 39 12 27
> 3 19 10 9 0.229
Tumor grade
(n = 227)
G1 9 4 5
G2 100 43 57
G3 118 46 72 0.788
Lymphatic invasion (n = 207) L0 68 33 35
L1 139 55 84 0.234
Invasion depth in mm (n = 195) geometric mean 14.2 14.3 (n = 90) 14.1 (n = 105) 0.856
Patients age in years (n = 233) mean 48.8 48.3 49.1 0.662
SCC-Ag in μg/L (n = 156) geometric mean 1.9 2.5 (n = 64) 1.5 (n = 92) 0.012
s-ALCAM in ng/mL (n = 55) geometric mean 28.3 29.0 (n = 21) 27.8 (n = 34) 0.515
Progression-free survival in months (PFS; n = 47) median 13 9 (n = 19) 15 (n = 28) 0.208
Ihnen et al. BMC Cancer 2012, 12:140
http://www.biomedcentral.com/1471-2407/12/140
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3) and percentage of positive cells (0:none, 1: 1-20%, 2:
21-50%; 3: 51-80%, 4: > 80%) resulting in a score from
0-12 [17]. For statistical evaluation the cohort was
separated into two groups: One included absent or
only focal and punctual ALCAM staining (IRS 0-1;
referred “ALCAM-negative”), the second group showed
weak to strong ALCAM expression and was assessed
as “ALCAM-positive” (IRS 2-12). No separate evalua-
tion of membraneous and cytoplasmic immunostaining
was performed.
Detection of soluble human ALCAM (s-ALCAM) in serum
samples
For the detection of s-ALCAM in 55 serum samples of
tumor patients, 96-well microtiter plates (Costar 9019)
were coated with 50 μl per well of 2 μg/ml of capturing
antibody MAB6561 (R&D systems, Minneapolis, Minne-
sota) overnight at 4°C, and the ELISA reaction was per-
formed as described [18]. Human ALCAM-Fc protein
(R&D systems, Minneapolis, Minnesota) served as an
internal standard control.
Statistical analysis
We report frequencies and median/mean values for
categorical and continuous variables, respectively. If
necessary, continuous variables were log-transformed.
The Chi-square test was used to analyze the relation
between the ALCAM expression (positive/negative) and
categorial variables (lymph node involvement, histologic
subtype, invasion into lymphatic or blood vessels, grad-
ing and FIGO-stage). Two sample t- t e s tw a sa p p l i e dt o
compare continuous variables (age, SCC values and s-
ALCAM levels) with regard to ALCAM expression
groups and to analyse s-ALCAM levels within different
FIGO-stage groups, histologic subtype groups, groups of
nodal involvement and occurrence of preoperative dis-
tant metastases.
Pearson correlation was applied to compare serum
SCC and s-ALCAM levels. The impact of ALCAM
expression on OAS (overall survival; time from diagnosis
to death of any cause), CSS (cancer-specific survival;
time from diagnosis to death due to the cervical tumor)
and DFS (disease-free survival; time from diagnosis to
relapse) was investigated using Kaplan-Meier analysis
and log-rank tests, partly stratified for the applied ther-
apy-regimen. In addition, univariate and multivariate
Cox regression analysis was performed. Since 9% of
patients in this cohort died of other reasons than cervi-
cal carcinoma, we decided to focus on CSS and DFS in
statistical calculations. P values < 0.05, two tailed, were
considered significant. Statistical analysis was performed
using SPSS 15.0 and the Statistical Package R version
2.9.2.
Results
ALCAM distribution in cervical cancer and normal cervical
tissue
Evaluation of ALCAM immunostaining resulted in
immunoreactive scores (IRS) from 0 to 12 (Figure 1).
ALCAM expression patterns varied from focal staining
in specific tumor areas (Figure 2A-B) to ALCAM reac-
tivity in all tumor cells, with both membraneous and
cytoplasmic staining in varying proportions (Figure 2D
and Additional file 1). Staining intensity also varied
from very weak to strong. Interestingly, in most cervical
carcinomas which exhibit moderate ALCAM staining
levels, ALCAM reactivity seemed to be more accentu-
ated at the invasion front (Figure 2C). The normal sur-
face epithelium of the ectocervix (squamous
differentiation) and the endocervix (glandular differen-
tiation) showed no ALCAM reactivity.
A, ALCAM-negative tumor (IRS0; 200×); B, weak and
focal membraneous ALCAM staining (IRS1; 400×); C,
moderate staining pattern with prominent staining inten-
sity in the periphery of tumor (IRS6; 400×); D, strong
ALCAM expression in most tumor cells (IRS9; 200×)
For statistical analysis, we defined two groups accord-
ing to ALCAM reactivity: An ALCAM-negative group
(IRS 0-1), which contains ALCAM-negative tumors and
those exhibiting a punctual ALCAM staining and an
ALCAM-positive group (IRS 2-12). By using this classifi-
cation ALCAM staining was positive in 58.4% and nega-
tive in 41.6% of all cases.
Correlations of ALCAM staining with clinical and
histological tumor characteristics
ALCAM-positive and ALCAM-negative cervical carcino-
mas were first compared regarding their clinicopatholo-
gical markers (Table 2). No correlations between
ALCAM expression and the investigated clinicopatholo-
gical variables could be demonstrated except serum
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Figure 1 Distribution of ALCAM immunoreactive scores (IRS) in
cervical carcinomas (n. For evaluation of staining intensities:
see methods.
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Page 4 of 10SCC levels which showed a significant inverse correla-
tion with ALCAM expression levels (p = 0.012).
In the subcohort with follow-up information (n =
178), advanced FIGO stage, nodal involvement, invasion
depth and lymphatic invasion were associated with sig-
nificantly increased risk of recurrence or death in uni-
variate analysis (Table 3). In contrast, ALCAM positivity
or negativity did not show any association with patients’
survival in univariate analysis (Table 3) and Kaplan-
M e i e ra n a l y s i s( C S S :p=0 . 8 7 1 ;D F S :p=0 . 7 5 5 ;n o t
shown). In multivariate analysis including stage, grading,
nodal status, histological type and ALCAM expression,
only advanced stage and nodal involvement turned out
as significant indicators of shorter DFS and CSS (Addi-
tional file 2).
After stratification according to the applied adjuvant
therapy, untreated patients with ALCAM expression
appeared to have a shorter DFS and CSS, yet these dif-
ferences were not significant (Figure 3A, B). In patients
receiving radiotherapy, a tendency into the opposite
direction was observed, since ALCAM expression was
associated with prolonged survival in this group (Figure
3C, D). In patients who were treated with chemoradia-
tion (Figure 3E, F) this effect was most prominent, with
a significantly longer CSS (cumulative incidence rates at
96 months 8%, 95% CI 0%-23%, and 26%, CI 3%-43%, p
= 0.038) and DFS (cumulative incidence rates at 96
months 11%, CI 0%-26%, and 31%, CI 6%-49%, p =
0.051).
A and B, CSS and DFS in patients without further
treatment other than tumor excision (n = 86). C and D,
CSS and DFS in patients who received radio therapy
after tumor excision (n = 42). E and F, CSS and DFS in
patients who received chemo radiation after operation
(n = 50)
In addition to ALCAM, other prognostic factors like
FIGO-stage, lymph node involvement, grading, and pre-
operative metastasis could also influence patients’ out-
come. A multivariate analysis could not be performed
due to the small size of the observed subgroups. We
A B
C D
Figure 2 ALCAM staining patterns in squamous cervical carcinomas.
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logical markers in each therapy group and in the sub-
groups showing low and high ALCAM expression. By
this approach we could demonstrate that histopathologi-
cal and clinical tumor characteristics were similarly dis-
tributed between all groups, indicating that the
predictive effect of ALCAM expression was independent
and not due to associations with known prognostic
parameters in subgroups (Additional file 3).
S-ALCAM levels in serum of cervical cancer patients
s-ALCAM levels were analysed by ELISA in a subset of
patients (n = 55). The median s-ALCAM level was 27.6
ng/ml (range 17.5-55.1 ng/ml, mean 28.9 ng/ml). When
comparing the s-ALCAM levels to ALCAM expression
levels in cervical carcinoma tissue no significant associa-
tions were revealed (p = 0.515). We also correlated s-
ALCAM levels to clinicopathological factors as
described for ALCAM expression in tumor tissue. It
could be shown that moderately differentiated tumors
(G2) showed significantly higher s-ALCAM levels com-
pared to poorly differentiated carcinomas G3 (17.4%
increase, 95% CI 2.4%-29.7%, p = 0.016). G1 tumors
were excluded because of the low case number (n = 2).
However, no other significant associations could be
found and s-ALCAM levels were not associated with
patients’ outcome (not shown).
Discussion
In this hypothesis generating study ALCAM and s-
ALCAM expression levels in tumor tissue and sera of
cervical carcinoma patients were evaluated for the first
time. Here we were able to show that ALCAM expres-
sion in tumor cells might be a predictive marker for
response to chemoradiation in this cancer entity.
By evaluating ALCAM reactivity in tumor cells we
were able to show that ALCAM expression is present in
a substantial portion of tumors but does not correlate
with prognostic markers like clinical stage, grading, age
or histological type, or with patients’ survival. Although
few other groups distinguish between cytoplasmic and
membranous ALCAM expression in neoplastic tissue
following the idea that a stronger cytoplasmic expression
pattern might be abnormal and associated with tumor
progression [19-21], we refrained from separating
ALCAM expression in membraneous and cytoplasmic
staining for two reasons: first we found that cytoplasmic
and membranous ALCAM staining correlated positively
with each other, second, in cases of intense ALCAM
expression it is often difficult to assess the staining
intensity of each compartment properly (Additional file
1: Figure S1 and unpublished data).
Prior studies in other cancer entities have reported
that ALCAM is upregulated in some and downregulated
in others [8]. Contrary to our results high ALCAM
Table 3 Univariate analysis of clinicopathological prognostic factors (n = 178)
characteristics Hazard ratio 95% confidence interval p value*
disease-free survival (DFS)
Age (>/< median) 0.912 0.509-1.633 n.s.
FIGO stage (III/IV vs. II vs. I) 2.112 1.486-3.002 < 0.001
Nodal involvement (N1 vs. N0) 3.125 1.750-5.579 < 0.001
Grading (G3 vs. G1/G2) 1.164 0.656-2.066 n.s.
histological type (adenomatous/adenosquamous vs. squamous) 1.118 0.597-2.093 n.s.
lymphatic invasion (L1 vs. L0) 2.934 1.300-6.621 0.010
depth of invasion (> 10 mm vs. 1-10 mm) 3.303 1.448-7.531 0.004
Adjuvant therapy (radiation vs. none) 1.834 0.961-3.499 0.066
Adjuvant therapy (chemoradiation vs.nNone) 0.743 0.325-1.699 n.s.
ALCAM IHC (positive vs. negative) 0.912 0.509-1.633 n.s.
cancer-specific survival (CSS)
Age (>/< median) 1.011 0.472-1.638 n.s.
FIGO stage (III/IV vs. II vs. I) 2.265 1.555-3.299 < 0.001
Nodal involvement (N1 vs. N0) 3.664 1.972-6.811 < 0.001
Grading (G3 vs. G1/G2) 1.325 0.715-2.457 n.s.
histological type (adenomatous/adenosquamous vs. squamous) 1.012 0.507-2.020 n.s.
lymphatic invasion (L1 vs. L0) 2.960 1.232-7.113 0.015
depth of invasion (> 10 mm vs. 1-10 mm) 3.221 1.325-7.831 0.010
Adjuvant therapy (radiation vs. none) 1.840 0.930-3.643 0.080
Adjuvant therapy (chemoradiation vs. none) 0.674 0.266-1.713 n.s.
ALCAM IHC (positive vs. negative) 0.880 0.472-1.638 n.s.
*significant p-values are shown in bold
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ciated with reduced survival or unfavourable prognostic
markers in some tumor types, i.e. colorectal [4,7], oral
[10,21], esophageal [11], pancreatic [22] and gastric car-
cinomas [23] as well as neuroblastoma [24]. However,
similar to previous studies in breast cancer, our results
indicate that ALCAM might represent a predictive mar-
ker in cervical cancer: In patients who did not receive
any further therapy after tumor excision, high ALCAM
expression levels were associated with shorter CSS and
DFS, whereas in patients receiving adjuvant chemoradia-
tion high ALCAM expression was indicative of a better
Figure 3 Survival analysis of low (IRS 0-1) and high (IRS 2-12) ALCAM staining.
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analysed ALCAM expressioni nt u m o rt i s s u e so np r o -
tein and mRNA level using c-DNA microarray data and
western blot analysis [12]. Similar to the present data
obtained in cervical carcinomas, ALCAM expression
was not relevant for prognosis in the total breast cancer
cohort. However, in the subgroup of chemotherapy-trea-
ted patients, high ALCAM expression levels were asso-
ciated with significantly longer DFS and CSS. These
results could be at least partly explained by our experi-
mental study where ALCAM expression was increased
or silenced by stable transfection in breast cancer cell
lines: In those cells, the consequences of high ALCAM
expression were complex and included enhanced inva-
sive potential (which might result in a more aggressive
tumor growth) and increased apoptosis (which might
lead to higher chemosensitivity and a better prognosis
in chemotherapy-treated patients) [25]. In pancreatic
cancer cells, a reduced ALCAM expression has also
been shown to be associated with chemoresistance, in
that case to gemcitabine and actinomycin D [13]. The
results of our present study suggest that the conse-
quences of high ALCAM expression might be similar in
cervical cancer cells.
Comparison of the subcohorts treated with radiother-
apy alone and with chemoradiation suggests that
ALCAM expression is more predictive for successful
chemotherapy compared to radiation. The mechanisms
of resistance to radiotherapy and resistance to che-
motherapy share similar features (role of apoptosis) as
well as different characteristics (i.e. drug activation and
accumulation in chemoresistance, and DNA repair
mechanisms in radioresistance). Our results indicate
that both mechanisms might be influenced by ALCAM
in different, as yet unknown ways.
Since ALCAM is shedded into the blood by proteases,
we also analysed s-ALCAM levels in a subcohort of 55
patients. The resulting s-ALCAM levels in our patients
(mean 28.9 ng/ml) are below those reported for breast
cancer patients (74 ng/ml; [15]) and ovarian cancer
patients (mean 44 ng/ml; [14]), but slightly above those
found in patients with esophageal carcinoma (mean 23.9
ng/ml; [26]). Healthy control groups showed mean s-
ALCAM levels of 60 ng/ml [15], 20.6 ng/ml [26] and 29
ng/ml [14], respectively. During our experiments, there
was no control group available which was comparable
to the patients with respect of sex, age and sample sto-
rage. Yet, the low s-ALCAM levels in our cervical can-
cer cohort and the lack of association of s-ALCAM
values with ALCAM immunostaining in cancer tissue or
patients’ o u t c o m es u g g e s t st h a ts - A L C A Mi sn o ta n
acceptable serum biomarker in this tumor type.
For squamous cell carcinomas of the cervix or other
sites there are only a few studies available, which
provide predictive markers for response to radiotherapy
or chemotherapy, mainly by analysing cDNA expression
arrays [27-29]. Adhesion molecules have been identified
to be involved in chemoresistance in some prior studies
on different cancer types: In neuroblastoma cell lines,
acquired resistance to vincristine and doxorubicine was
associated with downregulation of the neural cell adhe-
sion molecule (NCAM) [30]. Similarly, paclitaxel-resis-
tant ovarian carcinoma cell lines showed a decreased
expression of the epithelial adhesion molecule E-cad-
herin [31]. ALCAM silencing has been shown to induce
chemoresistance in pancreatic cancer cells in vitro [13].
In breast cancer patients [12] and in this study analysing
cervical cancer patients, ALCAM expression in cancer
tissue correlates with increased sensitivity to chemora-
diation or chemotherapy which might at least partly
result from its influence on apoptosis [25].
Limitations of this study are its retrospective design
and the heterogeneous group of patients with relatively
small numbers in the treatment groups. However, the
heterogeneity in this first, hypothesis-generating study
on ALCAM expression in cervical cancer led to interest-
ing data which suggest that the impact of ALCAM over-
expression might be treatment-dependent. To further
investigate the potential predictive value of ALCAM
expression for chemoradiation in cervical cancer, it will
be necessary to investigate ALCAM expression levels in
a prospective manner, using i.e. tissue biopsies of
patients with advanced disease (FIGO III/IV) to analyse
outcome after chemoradiation.
Conclusion
In summary we hypothesize, that ALCAM expression in
cervical carcinoma might be associated with improved
chemoradiation response. Although the exact underlying
mechanisms remain unclear, these results might help to
stratify patients, who would benefit from a combined
chemoradiation therapy in cervical cancer.
Additional material
Additional file 1: Figure S1: Cytoplasmic and membraneous ALCAM
reactivity. Examples of ALCAM immunostaining in three cervical
carcinomas showing concomitant cytoplasmic and membraneous
ALCAM reactivity in tumor cells.
Additional file 2: Table S1: Multivariate analysis in the total cohort.
The table shows a Cox regression analysis for disease-free survival (DFS)
and cancer-specific survival (CSS) in the total cohort including FIGOn
stage, nodal involvement, grading, histological type, and ALCAM
immunoreactivity.
Additional file 3: Table S2: Distribution of clinical and histological
prognostic factors among subcohorts of cervical cancer patients.
After stratification according to the applied therapy, a multivariate
analysis could not be performed due to the small subgroup sizes. We
therefore analysed the distribution of the clinicopathological prognostic
markers in each therapy group and in the subgroups showing low and
high ALCAM expression. By this approach we could demonstrate that
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distributed between all groups, indicating that the predictive effect of
ALCAM expression in the chemoradiation group was independent.
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